News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
715,164 Results
Type
Article (42321)
Company Profile (294)
Press Release (672549)
Section
Business (210370)
Career Advice (2091)
Deals (36628)
Drug Delivery (106)
Drug Development (83012)
Employer Resources (175)
FDA (16545)
Job Trends (15393)
News (355892)
Policy (33877)
Tag
2024 BioCapital Digital (12)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (11)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (6)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (6)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2590)
Accelerated approval (2)
Adcomms (21)
Allergies (82)
Alliances (51366)
ALS (85)
Alzheimer's disease (1361)
Antibody-drug conjugate (ADC) (113)
Approvals (16538)
Artificial intelligence (240)
Autoimmune disease (15)
Automation (14)
Bankruptcy (371)
Best Places to Work (11770)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (188)
Bladder cancer (56)
Brain cancer (26)
Breast cancer (247)
Cancer (1970)
Cardiovascular disease (155)
Career advice (1749)
Career pathing (30)
CAR-T (141)
Cell therapy (395)
Cervical cancer (16)
Clinical research (67161)
Collaboration (770)
Compensation (449)
Complete response letters (24)
COVID-19 (2651)
CRISPR (40)
C-suite (205)
Cystic fibrosis (101)
Data (1870)
Decentralized trials (2)
Denatured (25)
Depression (39)
Diabetes (245)
Diagnostics (6406)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (111)
Drug pricing (107)
Drug shortages (28)
Duchenne muscular dystrophy (82)
Earnings (87732)
Editorial (33)
Employer branding (21)
Employer resources (149)
Events (114392)
Executive appointments (641)
FDA (17634)
Featured Employer (50)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (688)
Gene editing (101)
Generative AI (20)
Gene therapy (285)
GLP-1 (714)
Government (4497)
Grass and pollen (4)
Guidances (48)
Healthcare (18983)
Huntington's disease (23)
IgA nephropathy (22)
Immunology and inflammation (110)
Indications (27)
Infectious disease (2778)
Inflammatory bowel disease (134)
Inflation Reduction Act (8)
Influenza (45)
Intellectual property (84)
Interviews (322)
IPO (16763)
IRA (47)
Job creations (4055)
Job search strategy (1492)
Kidney cancer (9)
Labor market (33)
Layoffs (469)
Leadership (16)
Legal (8367)
Liver cancer (71)
Lung cancer (281)
Lymphoma (130)
Machine learning (2)
Management (59)
Manufacturing (274)
MASH (60)
Medical device (13394)
Medtech (13399)
Mergers & acquisitions (20318)
Metabolic disorders (637)
Multiple sclerosis (67)
NASH (17)
Neurodegenerative disease (78)
Neuropsychiatric disorders (26)
Neuroscience (1837)
NextGen: Class of 2025 (6636)
Non-profit (4524)
Northern California (2366)
Now hiring (36)
Obesity (347)
Opinion (226)
Ovarian cancer (71)
Pain (85)
Pancreatic cancer (76)
Parkinson's disease (130)
Partnered (18)
Patents (202)
Patient recruitment (91)
Peanut (48)
People (59006)
Pharmaceutical (91)
Pharmacy benefit managers (19)
Phase I (20833)
Phase II (29552)
Phase III (22149)
Pipeline (918)
Podcasts (73)
Policy (119)
Postmarket research (2654)
Preclinical (8820)
Press Release (68)
Prostate cancer (91)
Psychedelics (31)
Radiopharmaceuticals (248)
Rare diseases (365)
Real estate (6251)
Recruiting (67)
Regulatory (22950)
Reports (46)
Research institute (2365)
Resumes & cover letters (358)
Rett syndrome (3)
RNA editing (2)
RSV (37)
Schizophrenia (69)
Series A (122)
Series B (77)
Service/supplier (12)
Sickle cell disease (52)
Southern California (2046)
Special edition (15)
Spinal muscular atrophy (150)
Sponsored (29)
Startups (3721)
State (2)
Stomach cancer (13)
Supply chain (60)
The Weekly (45)
United States (20870)
Vaccines (672)
Venture capitalists (37)
Webinars (12)
Weight loss (239)
Women's health (32)
Worklife (15)
Date
Today (149)
Last 7 days (584)
Last 30 days (2936)
Last 365 days (34209)
2025 (7492)
2024 (35769)
2023 (40633)
2022 (51798)
2021 (56329)
2020 (54791)
2019 (47398)
2018 (35770)
2017 (33141)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (780)
Alabama (49)
Alaska (7)
Arizona (228)
Arkansas (14)
Asia (40543)
Australia (6496)
California (5419)
Canada (1855)
China (466)
Colorado (242)
Connecticut (255)
Delaware (125)
Europe (86439)
Florida (801)
Georgia (188)
Idaho (57)
Illinois (495)
India (23)
Indiana (294)
Iowa (9)
Japan (138)
Kansas (99)
Kentucky (23)
Louisiana (7)
Maine (60)
Maryland (823)
Massachusetts (4118)
Michigan (210)
Minnesota (367)
Mississippi (2)
Missouri (75)
Montana (27)
Nebraska (25)
Nevada (56)
New Hampshire (62)
New Jersey (1543)
New Mexico (29)
New York (1558)
North Carolina (922)
North Dakota (7)
Northern California (2366)
Ohio (190)
Oklahoma (14)
Oregon (38)
Pennsylvania (1228)
Puerto Rico (9)
Rhode Island (25)
South America (1160)
South Carolina (17)
South Dakota (1)
Southern California (2046)
Tennessee (92)
Texas (807)
Utah (164)
Virginia (135)
Washington D.C. (57)
Washington State (512)
West Virginia (3)
Wisconsin (50)
715,164 Results for "alexion pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
AstraZeneca Axes Two Alexion Assets as Q4 Earnings Exceed Expectations
Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” deal for the pharma.
February 6, 2025
·
3 min read
·
Tristan Manalac
Business
JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo® Technology for Neurodegenerative Disease in Research Collaboration with Alexion
JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo ® Technology for Neurodegenerative Disease in Research Collaboration with Alexion.
March 19, 2024
·
4 min read
Business
Alexion Canada Appoints Karen Heim as New General Manager
Alexion Pharma Canada Corp., AstraZeneca’s Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024.
April 2, 2024
·
3 min read
Press Releases
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)
December 18, 2024
·
5 min read
Press Releases
Universe Pharmaceuticals INC Announces Share Consolidation
March 20, 2025
·
3 min read
Press Releases
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
October 25, 2024
·
8 min read
Business
JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo® Technology
JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida: “JCR”) announces that it has signed a Research Collaboration, Option and License Agreement with Alexion, AstraZeneca Rare Disease (“Alexion”) for the development of novel oligonucleotide therapeutics to support targeted delivery to certain tissues or organs using J-Brain Cargo®, JCR’s proprietary blood-brain barrier (BBB)-penetrating technology.
December 21, 2023
·
5 min read
Press Releases
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program
March 25, 2025
·
4 min read
Press Releases
Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering
March 10, 2025
·
6 min read
Press Releases
Jabil Acquires Pharmaceutics International, Inc. (Pii)
February 4, 2025
·
4 min read
1 of 71,517
Next
